Trial site
Mount Sinai Union Square
New York, New York 10003, United StatesNot linked to an institution yet
- 15running trials
- 7closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 25 trials
- Phase 2/31 trial
- Status
- Active, not recruiting12 trials
- Completed6 trials
- Recruiting3 trials
- Suspended1 trial
- Terminated1 trial
- Lead sponsor
- National Cancer Institute (NCI)16 trials
- ECOG-ACRIN Cancer Research Group2 trials
- NRG Oncology2 trials
- Alliance for Clinical Trials in Oncology1 trial
- GOG Foundation1 trial
- and 1 more
Running trials
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· Phase 3· NRG Oncology· Source
Contact: Daniel R. Dickstein (principal investigator)
Recruiting
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667· Phase 2· National Cancer Institute (NCI)· Source
Contact: Richard L. Bakst (principal investigator)
Recruiting
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Bobby Liaw (principal investigator)
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Source
Active, not recruiting
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
NCT02115282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source
Active, not recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
NCT00098475· Phase 3· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error